The DOI matches its Crossref record; 171 of the 172 references it cites were found in a registry or an index.
The Canadian Network for Mood and Anxiety Treatments (Canmat) Task Force Recommendations for the Management of Patients with Mood Disorders and Comorbid Attention-Deficit/Hyperactivity Disorder
Abstract
Background: Patients with bipolar disorder (BD) and major depressive disorder (MDD) experience adult attention-deficit/hyperactivity disorder (ADHD) at rates substantially greater than the general population. Nonetheless, ADHD frequently goes untreated in this population. Methods: We reviewed the literature regarding the management of adult ADHD in patients with mood disorders. Because a limited number of studies have been conducted in adults, our treatment recommendations also are partly informed by research in children and adolescents with BD+ADHD or MDD+ADHD, adults with ADHD, and our clinical experience. Results: In individuals with mood disorders, ADHD is best diagnosed when typical symptoms persist during periods of sustained euthymia. Individuals with BD+ADHD, particularly those with bipolar I disorder (BD I), are at risk for mood destabilization with many ADHD treatments, and should be prescribed mood-stabilizing medications before initiating ADHD therapies. Bupropion is a reasonable first-line treatment for BD+ADHD, while mixed amphetamine salts and methylphenidate also may be considered in patients determined to be at low risk for manic switch. Modafinil and cognitive-behavioral therapy (CBT) are second-line choices. In patients with MDD+ADHD and moderate to severe depression, MDD should be the treatment priority, whereas in mildly depressed or euthymic patients the order may be reversed. First-line treatments for MDD+ADHD include bupropion, an antidepressant plus a long-acting stimulant, or an antidepressant plus CBT. Desipramine, nortriptyline, and venlafaxine are second-line options. Conclusions: Clinicians should be vigilant in screening for comorbid ADHD in mood disorder patients. ADHD symptoms can respond to appropriately chosen treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with comorbid ADHD often experience a more treatment‐refractory course, more mood episodes, greater functional impairment and a heightened risk of suicide.765”
In the citing paper
“For ADHD, CBT can improve both depressive and ADHD symptoms.”
From Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder (2016) · cites this paper as [22]
In the citing paper
“Studies of neurotransmitters have also pointed to abnormalities in dopamine (DA) and norepinephrine (NE) signaling [16,45]”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [16]
In the citing paper
“Neuroimaging studies have implicated differences in volume and activity in the frontal lobe, which is responsible for attention, behaviour selection, and emotion [16].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [16]
In the citing paper
“However, there is a theoretical risk of stimulant therapy resulting in mood destabilization in individuals with bipolar disorder [16].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [16]
In the citing paper
“Antidepressants such as venlafaxine and bupropion have also been evaluated as treatment options for ADHD, with some evidence of benefit in addressing ADHD symptoms [16,109].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [16]
In the citing paper
“However, it has also been noted that ADHD treatment may not be as effective in individuals with active depression [16].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [16]
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Yatham, L. N., & Malhi, G. S. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,515
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.885 · Cited by 1,421
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., De Girolamo, G., Haro, J. M., Karam, E. G., Lara, C., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.034389 · Cited by 1,321
Research works printed but not linked: 4
- DoyleAE. Executive functions in attention- deficit/hyperactivity disorder. J Clin Psychiatry. 2006; 67(suppl 8):21–26.
- FischerM. Persistence of ADHD into adulthood: it depends on whom you ask. ADHD Report. 1997;5:8–10.
- ConnersCK, ErhardtT, SparrowE. CAARS adult ADHD rating scales. North Tonawanda, NY: MultiHealth Systems Inc.; 1998.
- WeissMD. Diagnosis of childhood-onset conditions in adult psychiatry. Primary Psychiatry. 2010;17:21–28.
Cited by
Sorted by citations
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationAdult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
“As such, one can imagine this low hedonic tone as a key feature shared by MDD and resulting from a shared dysfunction in monoamine signaling, particularly in the ventral striatum [52].”
BackgroundResultInfluentialParikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Self-citationFountoulakis, K. Ν., Grunze, H., Vieta, E., Young, A. H., Yatham, L. N., Blier, P., Kasper, S. F., & Moeller, H. J. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw109 · Cited by 248
The vigilance regulation model of affective disorders and ADHD
Hegerl, U., & Hensch, T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.008 · Cited by 212
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“…MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b; Rosenbluth et al. 2012; Schaffer et al. 2012), the British Association…”
BackgroundCognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options
MacQueen, G. M., & Memedovich, K. A. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12463 · Cited by 172
Diminished effort on a progressive ratio task in both unipolar and bipolar depression
Hershenberg, R., Satterthwaite, T. D., Daldal, A., Katchmar, N., Moore, T. M., Kable, J. W., & Wolf, D. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.003 · Cited by 157
“Given mixed evidence for antidepressant use in bipolar disorder, including those enhancing dopaminergic function (Bond et al., 2012; Goldberg et al., 2004; Pacchiarotti et al., 2013), objective measures of amotivation could help tailor individualized risk-benefit calculations for using”
Lorenzo, R. D., Balducci, J., Poppi, C., Arcolin, E., Cutino, A., Ferri, P., D’Amico, R., & Filippini, T. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.23 · Cited by 159
Fountoulakis, K. Ν., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Kasper, S. F., & Moeller, H. J. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 117
An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder
da Silva, B. S., Grevet, E. H., Silva, L. C. F., Ramos, J. K. N., Rovaris, D. L., & Bau, C. H. D. (2023) · Discover Mental Health · doi:10.1007/s44192-022-00030-1 · Cited by 146
“The prescription of this medication might be specially considered as an option when comorbid conditions such as mood disorders or nicotine dependence are present, considering its primary antidepressant effect and its contribution to smoking cessation [200, 201].”
BackgroundOluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“Because patients with MDD have a 2-fold higher prevalence of ADHD relative to the general population and the presence and severity of comorbid ADHD can inform treatment selection for both conditions (Canadian Attention Deficit Hyperactivity Disorder Resource Alliance, 2011; Bond et al., 2012), the authors recommend as…”
MethodSelf-citationSandstrom, A., Perroud, N. A., Alda, M., Uher, R., & Pavlová, B. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13283 · Cited by 103
Katzman, M., & Sternat, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111818 · Cited by 83
“148,149 As well, individuals with MDD and ADHD experience higher levels of substance use and psychosocial impairment than each disorder in isolation, 150–153 suggesting a potential variant of MDD, and therefore explaining the treatment resistance in this population when treated with traditional…”
Personality Disorders in Older Adults: Emerging Research Issues
van Alphen, S. P. J., van Dijk, S. D. M., Videler, A. C., Rossi, G. M. P., Dierckx, E., Bouckaert, F., & Voshaar, R. C. O. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0538-9 · Cited by 71
Mak, A. D. P., Lee, S., Sampson, N. A., Albor, Y., Alonso, J., Auerbach, R. P., Baumeister, H., Benjet, C. L., Bruffaerts, R., Cuijpers, P. J., et al. (2021) · Journal of Attention Disorders · doi:10.1177/10870547211057275 · Cited by 83
“At present, evidence on effective treatment for ADHD with comorbidities in adults have been confined to individual comorbidities such as bipolar disorder, depression, or anxiety (Bond et al., 2012; CADDRA, 2018; Katzman et al., 2017).”
BackgroundPhilipsen, A. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.91 · Cited by 57
Liu, C., Hua, M.-H., Lu, M., & Goh, K. K. (2023) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12455 · Cited by 60
Adult ADHD and comorbid anxiety and depressive disorders: a review of etiology and treatment
Fu, X., Wu, W., Wu, Y., Liu, X., Liang, W., Wu, R., & Li, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1597559 · Cited by 54
Use of Stimulants in Bipolar Disorder
Perugi, G., Vannucchi, G., Bedani, F., & Favaretto, E. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0758-x · Cited by 53
Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis
Wang, S., Han, C., Lee, S.-J., Jun, T., Patkar, A. A., Masand, P. S., & Pae, C. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.034 · Cited by 55
“Despite multiple pharmacological agents available, a large proportion of children and adolescents with ADHD do not gain adequate response (Bond et al., 2012).”
BackgroundGao, K., Wang, Z., Chen, J., Kemp, D. E., Chan, P. K., Conroy, C. M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.12.004 · Cited by 45
Torres, I., Gómez-Barros, N., Colom, F., Jiménez, E., Bosch, R., Bonnín, C. D. M., Martínez‐Arán, A., Casas, M., Vieta, E., Ramos‐Quiroga, J. A., et al. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12426 · Cited by 46
“Regarding other clinical features, several previous studies (15, 17–19) had described an earlier age of onset of BD in the comorbid group, although this was not found in all the studies (16, 20, 22).”
BackgroundResultKatzman, M. A., & Sternat, T. (2014) · CNS Drugs · doi:10.1007/s40263-014-0175-1 · Cited by 40
“[6 7 ] R an d o m iz ed , d o u b le -b li n d ,”
BackgroundPrescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study
Cressman, A. M., Macdonald, E. M., Huang, A., Gomes, T., Paterson, M. J., Kurdyak, P. A., Mamdani, M. M., & Juurlink, D. N. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000406 · Cited by 37
Jerrell, J. M., McIntyre, R. S., & Park, Y. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-014-0541-z · Cited by 37
Self-citationCobos, J. P. D. L., Siñol, N., Pérez, V., & Trujols, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12045 · Cited by 38
Integrating Bipolar Disorder Management in Primary Care
Kilbourne, A. M., Goodrich, D. E., O’Donnell, A. N., & Miller, C. J. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0325-4 · Cited by 32
Perugi, G., Pallucchini, A., Rizzato, S., Pinzone, V., & Rossi, P. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1618270 · Cited by 35
“Due to a substantial overlap between mood and ADHD symptoms, it could be difficult to differentiate between the two conditions and some authors speculate that this large comorbidity is often an artifact [45].”
BackgroundNicola, M. D., Sala, L., Romo, L., Catalano, V., EVEN, C., Dubertret, C., Martinotti, G., Camardese, G., Mazza, M., Tedeschi, D., et al. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0456-6 · Cited by 33
“The greater burden associated with the ADHD phenotype in mood disorder populations hints at the need for adequately designed clinical trials aiming to establish safe and effective pharmacological and psychosocial approaches in individuals meeting criteria for both conditions [10].”
BackgroundMcIntyre, R. S., Alsuwaidan, M. T., Soczynska, J. K., Szpindel, I., Bilkey, T. S., Almagor, D., Woldeyohannes, H. O., Powell, A. M., Cha, D. S., Gallaugher, L. A., et al. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2325 · Cited by 31
Self-citationComorbidity of Adult Attention Deficit and Hyperactivity Disorder in Bipolar and Unipolar Patients
HARMANCI, H., Çelıkel, F. Ç., & Etikán, Í. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.11328 · Cited by 31
“In adults with major depressive disorder (MDD), the prevalence of co-occurring ADHD was 5%–12% (6,7,8).”
BackgroundSchoretsanitis, G., de León, J., Eap, C. B., Kane, J. M., & Paulzen, M. (2019) · CNS Drugs · doi:10.1007/s40263-019-00683-7 · Cited by 28
Comorbidities in Youth with Bipolar Disorder: Clinical Features and Pharmacological Management
Sesso, G., Brancati, G. E., & Masi, G. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220706104117 · Cited by 31
“…that psychostimulants and other ADHD medications may be particularly effective in treating ADHD in people with mood disorders, while future research should be aimed to explore different treatment options, as well as acceptability, safety and efficacy of treating ADHD along with mood symptoms [59].”
BackgroundVannucchi, G., Medda, P., Pallucchini, A., Bertelli, M. O., Angst, J., Azorin, J., Bowden, C. L., Vieta, E., Young, A. H., Mosolov, S. N., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.089 · Cited by 27
Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder
McIntyre, R. S., Lee, Y. L., Carmona, N. E., Subramaniapillai, M., Cha, D. S., Lee, J., Lee, J.-H., Alageel, A. A. S., Rodrigues, N. B., Park, C., et al. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000171 · Cited by 30
Self-citationBennett, F., Hodgetts, S., Close, A. J., Frye, M. A., Grunze, H., Keck, P. E., Kupka, R., McElroy, S. L., Nolen, W. A., Post, R. M., et al. (2019) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0169-5 · Cited by 29
Leopold, K., Ratzer, S., Correll, C. U., Rottmann‐Wolf, M., Pfeiffer, S., Ritter, P. S., Bauer, M., & Pfennig, A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.009 · Cited by 28
“Similarly, increased rates of comorbid ADHD in childhood in patients developing BD are reported (Bond et al., 2012).”
BackgroundLow Risk for Switch to Mania during Treatment with Sleep Promoting Antidepressants
Wichniak, A., Jarkiewicz, M., Okruszek, Ł., Wierzbicka, A., Holka-Pokorska, J., & Rybakowski, J. (2015) · Pharmacopsychiatry · doi:10.1055/s-0034-1396802 · Cited by 28
Attention-deficit/hyperactivity disorder in adults: update on clinical presentation and care
Asherson, P. J., Manor, I., & Huß, M. (2014) · Neuropsychiatry · doi:10.2217/npy.14.16 · Cited by 27
Guerdjikova, A. I., & McElroy, S. L. (2013) · Europe PMC (PubMed Central) · Cited by 23
Ekinci, S., Özdel, K., Öncü, B., Çolak, B., Kandemır, H., & Canat, S. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.2.137 · Cited by 23
Risk of Excessive Daytime Sleepiness Associated to Major Depression in Adolescents
Boz, S., Lanquart, J., Mungo, A., Delhaye, M., Loas, G., & Hein, M. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09922-x · Cited by 19
Liu, Y. S., Cao, B., & Chokka, P. R. (2022) · Journal of Attention Disorders · doi:10.1177/10870547221136228 · Cited by 21
“For ADHD patients with a comorbid MDD, treatment options may include medications that may benefit both MDD and ADHD symptoms such as Bupropion (Bond et al., 2012).”
BackgroundHigh Resolution Mapping of Modafinil Induced Changes in Glutamate Level in Rat Brain
Haris, M., Singh, A. K., Cai, K., Nath, K., Verma, G., Nanga, R. P. R., Hariharan, H., Detre, J. A., Epperson, N., & Reddy, R. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103154 · Cited by 19
Mucci, F., Avella, M. T., & Marazziti, D. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190805153610 · Cited by 21
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 18
The Characteristics of Mood Polarity, Temperament, and Suicide Risk in Adult ADHD
Giupponi, G., Innamorati, M., Rogante, E., Sarubbi, S., Erbuto, D., Maniscalco, I., Sanna, L., Conca, A., Lester, D., & Pompili, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082871 · Cited by 20
Getting depression clinical practice guidelines right: time for change?
Kuiper, S., Mclean, L., Fritz, K., Lampe, L., & Malhi, G. (2013) · Acta Psychiatrica Scandinavica Supplementum · doi:10.1111/acps.12176 · Cited by 18
Management of inter-episodic periods in patients with bipolar disorder
Samalin, L., Murru, A., & Vieta, E. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1176530 · Cited by 18
Women with Special Educational Needs. Policies & ICT for Integration & Equality
Bakola, L. N., Chaidi, I., Drigas, A. S., Skianis, C. A., & Karagiannidis, C. (2022) · Technium Social Sciences Journal · doi:10.47577/tssj.v28i1.5708 · Cited by 16
MacDonald, L., & Sadek, J. R. (2023) · Brain Sciences · doi:10.3390/brainsci13111517 · Cited by 20
McIntyre, R. S., Rosenbluth, M., Ramasubbu, R., Bond, D. J., Taylor, V. H., Beaulieu, S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400209 · Cited by 70
Self-citationKim, J. S., Oh, S., Jeon, H. J., Hong, K. S., & Baek, J. H. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.06.009 · Cited by 15
Obesity and Mental Illness: Implications for Cognitive Functioning
McIntyre, R. S., Cha, D. S., Jerrell, J. M., Soczynska, J. K., Woldeyohannes, H. O., Taylor, V. H., Kaidanovich‐Beilin, O., Alsuwaidan, M. T., & Ahmed, A. T. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0040-5 · Cited by 15
Self-citationKeller, K. L., Vollrath-Smith, F. R., Jafari, M., & Ikemoto, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3300-9 · Cited by 14
“Immediate actions may be warranted given the fact that combined medications of psychostimulant drugs with mood stabilizers are suggested for treatments of bipolar disorders that comorbid with attention-deficit/hyperactivity disorder (Bond et al. 2012).”
BackgroundAuditory evoked potentials and suicidal behaviors in patients with major depressive disorders
Kim, J. S., Kim, S., Lee, H.-S., Kwon, Y., Lee, H.-Y., & Shim, S.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-86602-7 · Cited by 14
Lifetime evolution of ADHD treatment
Mucci, F., Carpita, B., Pagni, G., Vecchia, A. D., Bjedov, S., Pozza, A., & Marazziti, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02336-w · Cited by 15
Pan, M., Dong, M., Zhang, S., Liu, L., Li, H., Wang, Y., & Qian, Q. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05673-8 · Cited by 16
Étain, B., Lajnef, M., Loftus, J., Henry, C., Raust, A., Gard, S., Kahn, J., Leboyer, M., Scott, J. L., & Bellivier, F. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416642021 · Cited by 13
“Indeed, some recommendations have been proposed for the management of patients with mood disorders and comorbid ADHD in national clinical guidelines (Bond et al., 2012).”
BackgroundKim, J. S., Kim, D.-W., Kwon, Y., Lee, H.-Y., Kim, S., & Shim, S. H. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.06.008 · Cited by 12
Huang, J., Ulke, C., & Strauss, M. (2019) · BMC Neuroscience · doi:10.1186/s12868-019-0526-4 · Cited by 10
Kim, E. J., Kwon, Y., Lee, H.-Y., Yoon, H. J., Kim, J. S., & Shim, S.-H. (2020) · Psychiatry Investigation · doi:10.30773/pi.2020.0074 · Cited by 10
Shim, S.-H., Woo, Y. S., Kim, J. S., Heo, I. S., Yoon, H. J., Sung, H. M., Lee, J., & Bahk, W. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.143 · Cited by 10
“The Canadian Network for Mood and Anxiety Treatments task force [17] recommends combining an SSRI”
BackgroundAmeringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 12
Self-citationTodor, I., Popa, A., Neag, M. A., Muntean, D. M., Bocșan, I. C., Buzoianu, A. D., Vlase, L., Gheldiu, A.-M., & Briciu, C. (2016) · Pharmacology · doi:10.1159/000452223 · Cited by 9
A transdiagnostic view on MDD and ADHD: shared cognitive characteristics?
van Hal, R., Geurts, D. E. M., van Eijndhoven, P., Kist, J. D., Collard, R. M., Tendolkar, I., & Vrijsen, J. N. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.07.028 · Cited by 12
Chiorean, A., Jones, B. D. M., Murong, M., Gonzalez‐Torres, C., Kloiber, S. M., Ortiz, A., Rosenblat, J. D., Mulsant, B. H., & Husain, M. I. (2024) · Bipolar Disorders · doi:10.1111/bdi.13440 · Cited by 8
“19 Given the potential efficacy of these agents in BD and high rates of comorbidity with psychiatric disorders such as ADHD, evaluation of their safety in precipitating mood episodes in BD is critical.”
Kashihara, J., Takebayashi, Y., Kunisato, Y., & Ito, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256902 · Cited by 9
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 7
Erdoğan, E., Delibaş, D. H., & Gülseren, Ş. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_448_18 · Cited by 7
Early optimized pharmacological treatment in patients with depression and chronic pain
Oluboka, O. J., Katzman, M. A., Habert, J., Khullar, A., Oakander, M. A., McIntosh, D., McIntyre, R. S., Soares, C. N., Lam, R. W. M., Klassen, L. J., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922000128 · Cited by 7
Self-citationMcIntyre, R. S., Fayyad, R. S., Mackell, J. A., & Boucher, M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1136603 · Cited by 6
Self-citationThe influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite
Todor, I., Popa, A., Neag, M., Muntean, D., Bocsan, C., Buzoianu, A., Vlase, L., Gheldiu, A., Chira, R., & Briciu, C. (2015) · Clujul Medical · doi:10.15386/cjmed-488 · Cited by 8
“The treatment recommendations for managing adult ADHD and depression are similar to those for children [21] and acknowledge as a third-line treatment option the association of atomoxetine and antidepressants [22].”
BackgroundOrsolini, L., Longo, G., Volgare, R., Piergentili, S., Servasi, M., Perugi, G., & Volpe, U. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.083 · Cited by 8
Management of Attention-Deficit/Hyperactivity Disorder in Primary Care
McCoy, K. T., Pancione, K., Hammonds, L. S., & Costa, C. B. (2019) · Nursing Clinics of North America · doi:10.1016/j.cnur.2019.08.001 · Cited by 4
Differentiating Pediatric Bipolar Spectrum Disorders from Attention-Deficit/Hyperactivity Disorder
Sala, R., Gill, M. K., & Birmaher, B. B. (2014) · Psychiatric Annals · doi:10.3928/00485713-20140908-04 · Cited by 3
Woo, Y. S., Hong, J., Shim, S.-H., Sung, H. M., Seo, J. S., Park, S., Lee, J. G., Yoon, B.-H., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1112 · Cited by 4
Vallabh, A. (2024) · Mental Health Clinician · doi:10.9740/mhc.2024.04.082 · Cited by 3
Li, D., Tsai, S., Chen, T., Kao, Y., Liang, C., & Chen, M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.071 · Cited by 3
The Treatment of Adult ADHD: Complexity at Hand
Pallanti, S., & Salerno, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-39051-8_19 · Cited by 3
Oliva, F., Carezana, C., Nibbio, G., Bramante, S., Pomeri, A. P., & Maina, G. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000320 · Cited by 3
Yazıcı, M., & Puşuroğlu, M. (2025) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2025.95 · Cited by 2
Adult ADHD in Bipolar and Related Disorders
Pallanti, S., & Salerno, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-39051-8_9 · Cited by 2
Brent, D. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.011 · Cited by 2
Joshi, G., & Wozniak, J. R. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.008 · Cited by 2
Sadek, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-45635-5_10 · Cited by 3
Managing major depressive disorder through the use of adjunct therapies
Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70001-0 · Cited by 2
“, 2012a), attention deficit hyperactivity disorder (ADHD) (Bond et al., 2012), chronic fatigue syndrome (Dansie et al.”
BackgroundTo Prescribe or Not? Pharmacological Options in Adult Attention-Deficit/Hyperactivity Disorder
Aoshima-Kilroy, A., Banu, S., Udoetuk, S., Shah, A. A., & Moukaddam, N. (2017) · Psychiatric Annals · doi:10.3928/00485713-20170510-01 · Cited by 1
Gondek, T. M., Todzia-Kornaś, A., & Szczegielniak, A. (2023) · Psychiatria Spersonalizowana · doi:10.5114/psychs.2023.135314 · Cited by 1
Lu, N., Wang, M., Zheng, Z., Zhang, F., Huang, W., Pan, H., Zhong, Y. J., Du, X., Zhang, G., Li, C., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116662 · Cited by 2
Begnaud, A., Cabelguen, C., Challet‐Bouju, G., Leboucher, J., Schreck, B., & Grall‐Bronnec, M. (2025) · Addictive Behaviors · doi:10.1016/j.addbeh.2025.108557 · Cited by 2
Syed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 1
Assessment and treatment of depressive disorders in adults with ADHD
Prince, J. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.009 · Cited by 1
Clinically Significant Interactions with Stimulants and Other Non-stimulants for ADHD
Kattura, R. S., & Crismon, M. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_21 · Cited by 1
Sadek, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-45635-5_9 · Cited by 1
Ishizuka, K., Ishiguro, T., Kawaguchi, D., Nomura, N., & Inada, T. (2023) · Psychiatry Research Communications · doi:10.1016/j.psycom.2023.100128 · Cited by 1
Symptomwandel und Komorbiditäten
Lam, A. P., & Philipsen, A. (2016) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-016-1435-3 · Cited by 1
Hyun, G. J., Kim, B., Kim, B.-N., Kim, J. I., Park, J. H., Bahn, G. H., Lee, M., Lee, S. I., Lee, Y. S., & Han, D. H. (2016) · 신경정신의학 · doi:10.4306/jknpa.2016.55.4.343 · Cited by 1
Metadata
- Authors
- Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M.
- Affiliations
- University of British Columbia (CA)
- University Health Network (CA)
- Douglas Mental Health University Institute (CA)
- Sunnybrook Health Science Centre (CA)
- Children's & Women's Health Centre of British Columbia (CA)
- Corresponding author
- Bond, David J.
- ORCID
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2012-02
- Volume
- 24
- Issue
- 1
- Pages
- 23-37
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W48669398
- Cited by
- 133
- References
- 172
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 13 · 2018: 7 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 13 · 2013: 12 · 2012: 7
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- attention deficit hyperactivity disorder, comorbidities, bipolar disorder, major depressive disorder, mood disorders, ADHD treatment, bupropion, mixed amphetamine salts, methylphenidate, modafinil, cognitive behavioral therapy, mood stabilizers, manic switch, ADHD screening, treatment guidelines
- MeSH terms
- Adult, Central Nervous System Stimulants, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Bipolar Disorder, Canada, Major Depressive Disorder, Humans, Comorbidity, Cognitive Behavioral Therapy, Lithium Compounds, Mood Disorders, Advisory Committees
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
